GB Sciences Inc (GBLX.PK)
GBLX.PK on OTC Markets Group
0.62USD
19 Apr 2018
0.62USD
19 Apr 2018
Change (% chg)
$-0.03 (-4.24%)
$-0.03 (-4.24%)
Prev Close
$0.65
$0.65
Open
$0.65
$0.65
Day's High
$0.65
$0.65
Day's Low
$0.60
$0.60
Volume
444,786
444,786
Avg. Vol
2,142,675
2,142,675
52-wk High
$1.56
$1.56
52-wk Low
$0.21
$0.21
About
GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution... (more)
No analyst recommendations are available for .
Overall
| Beta: | 0.03 |
| Market Cap(Mil.): | $101.20 |
| Shares Outstanding(Mil.): | 155.93 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| GBLX.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 17.62 | 42.11 |
| EPS (TTM): | -0.13 | -- | -- |
| ROI: | -141.11 | 6.48 | 60.71 |
| ROE: | -261.56 | 7.34 | 73.65 |
BRIEF-GB Sciences Announces The Appointment Of John Davis As Executive VP And General Counsel
* GB SCIENCES ANNOUNCES THE APPOINTMENT OF JOHN B. DAVIS AS EXECUTIVE VP AND GENERAL COUNSEL Source text for Eikon: Further company coverage:
BRIEF-GB Sciences Pursues FDA-Registered, First-In-Human Trial Of Cannabis Based Therapy For Parkinson's Disease
* COMPANY WILL BEGIN ITS TOXICOLOGY STUDIES IN SUMMER OF 2018 Source text for Eikon: Further company coverage:
Earnings vs. 
Estimates
No consensus analysis data available.